A40AEG Pentixapharm Holding AG

EQS-News: Pentixapharm Releases Interim Report for the Third Quarter of 2024

EQS-News: Pentixapharm Holding AG / Key word(s): Quarterly / Interim Statement
Pentixapharm Releases Interim Report for the Third Quarter of 2024

12.11.2024 / 17:45 CET/CEST
The issuer is solely responsible for the content of this announcement.


Pentixapharm Releases Interim Report for the Third Quarter of 2024
  • Loss of Pentixapharm Holding AG for the reporting period: €49k
  • No revenue realized during the stub fiscal year through the end of Q3
  • Current liabilities of €487k, mainly from the purchase of Pentixapharm AG shares

Berlin and Würzburg, Germany, November 12, 2024 – Pentixapharm Holding AG (ISIN: DE000A40AEG0), listed in the Prime Standard of the Frankfurt Stock Exchange, today published its consolidated interim report for the stub fiscal year from March 18 to September 30, 2024. Since the spin-off from Eckert & Ziegler SE, through which Pentixapharm AG and Myelo Therapeutics GmbH will be integrated into the group financial statements, was entered into the commercial register on October 2, 2024, this consolidated report includes only the figures for Pentixapharm Holding AG and does not yet contain results for either company.

During the reporting period, Pentixapharm Holding AG reported a loss of €49k, attributed to other operating expenses, primarily fees and charges related to the company’s establishment, acquisition of financial assets, and the spin-off. The interim report also shows no revenue, as operational business activities will commence only after the formal spin-off of Pentixapharm AG and Myelo Therapeutics GmbH.

For the 2024 consolidated annual financial statements, management anticipates a significant increase in losses in the fourth quarter due to the inclusion of Pentixapharm AG and Myelo Therapeutics GmbH from October 2, 2024, with an expected total loss of approximately –€8 million for the fiscal year.

The full interim report is available on the Pentixapharm Holding AG Investor Relations website: .

About Pentixapharm

Pentixapharm is a clinical-stage biotech company discovering and developing novel targeted radiopharmaceuticals with its offices in Berlin and Würzburg, Germany. It is committed to developing CXCR4 ligand-based first-in-class radiopharmaceutical approaches with a clear commercial pathway for diagnostic and therapeutic programs in a number of hematological and solid cancers, as well as cardiovascular, endocrine and inflammatory diseases.

 

For more information, please contact:

Pentixapharm Holding AG
Phillip Eckert, Investor Relations

Tel.



12.11.2024 CET/CEST Dissemination of a Corporate News, transmitted by EQS News - a service of EQS Group AG.
The issuer is solely responsible for the content of this announcement.

The EQS Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases.
Archive at -news.com


Language: English
Company: Pentixapharm Holding AG
Robert-Rössle-Straße 10
13125 Berlin
Germany
E-mail:
Internet: /
ISIN: DE000A40AEG0
WKN: A40AEG
Listed: Regulated Market in Frankfurt (Prime Standard); Regulated Unofficial Market in Berlin, Dusseldorf, Hamburg, Hanover, Munich, Stuttgart, Tradegate Exchange
EQS News ID: 2028371

 
End of News EQS News Service

2028371  12.11.2024 CET/CEST

fncls.ssp?fn=show_t_gif&application_id=2028371&application_name=news&site_id=research_pool~~~9efe1c65-8ece-4ff7-9608-f21c8e0a38a3
EN
12/11/2024

Underlying

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Pentixapharm Holding AG

 PRESS RELEASE

EQS-News: Pentixapharm veröffentlicht Zwischenbericht für das 3. Quart...

EQS-News: Pentixapharm Holding AG / Schlagwort(e): Quartals-/Zwischenmitteilung Pentixapharm veröffentlicht Zwischenbericht für das 3. Quartal 2024 12.11.2024 / 17:45 CET/CEST Für den Inhalt der Mitteilung ist der Emittent / Herausgeber verantwortlich. Pentixapharm veröffentlicht Zwischenbericht für das 3. Quartal 2024 Verlust der Pentixapharm Holding AG im Berichtszeitraum: 49 Tsd. € Keine Umsatzrealisierung im Rumpfgeschäftsjahr bis Ende Q3 Kurzfristige Verbindlichkeiten von 487 Tsd. €, hauptsächlich aus Aktienkauf der Pentixapharm AG Berlin und Würzburg, 12. Novembe...

 PRESS RELEASE

EQS-News: Pentixapharm Releases Interim Report for the Third Quarter o...

EQS-News: Pentixapharm Holding AG / Key word(s): Quarterly / Interim Statement Pentixapharm Releases Interim Report for the Third Quarter of 2024 12.11.2024 / 17:45 CET/CEST The issuer is solely responsible for the content of this announcement. Pentixapharm Releases Interim Report for the Third Quarter of 2024 Loss of Pentixapharm Holding AG for the reporting period: €49k No revenue realized during the stub fiscal year through the end of Q3 Current liabilities of €487k, mainly from the purchase of Pentixapharm AG shares Berlin and Würzburg, Germany, November 12, 2024 –...

 PRESS RELEASE

EQS-News: Pentixapharm begrüßt Entscheidung der Centers for Medicare &...

EQS-News: Pentixapharm Holding AG / Schlagwort(e): Stellungnahme Pentixapharm begrüßt Entscheidung der Centers for Medicare & Medicaid Services (CMS) zur Erstattung von diagnostischen Radiopharmazeutika 04.11.2024 / 17:26 CET/CEST Für den Inhalt der Mitteilung ist der Emittent / Herausgeber verantwortlich. Berlin und Würzburg, Deutschland, 4. November 2024 – Die Pentixapharm AG, ein Entwickler innovativer Radiopharmazeutika, begrüßt die kürzlich bekannt gegebene Entscheidung des U.S. Centers for Medicare & Medicaid Services (CMS), in amerikanischen Krankenhäusern separate...

 PRESS RELEASE

EQS-News: Pentixapharm Welcomes CMS Decision to Enhance Reimbursement ...

EQS-News: Pentixapharm Holding AG / Key word(s): Statement Pentixapharm Welcomes CMS Decision to Enhance Reimbursement for Diagnostic Radiopharmaceuticals 04.11.2024 / 17:26 CET/CEST The issuer is solely responsible for the content of this announcement. Berlin and Würzburg, Germany, November 4, 2024 – Pentixapharm, a biopharmaceutical company developing innovative first-in-class radiopharmaceuticals, welcomes the recent announcement by the U.S. Centers for Medicare & Medicaid Services (CMS) to implement separate payments for specialized diagnostic radiopharmaceuticals use...

 PRESS RELEASE

EQS-News: Pentixapharm Holding AG: US National Cancer Institute starte...

EQS-News: Pentixapharm Holding AG / Schlagwort(e): Studie Pentixapharm Holding AG: US National Cancer Institute startet fortgeschrittene klinische Studie mit PentixaFor 29.10.2024 / 11:46 CET/CEST Für den Inhalt der Mitteilung ist der Emittent / Herausgeber verantwortlich. Berlin und Würzburg, 29. Oktober 2024 – Das National Cancer Institute (NCI) und das National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), zwei angesehene Forschungsorganisationen der US-amerikanischen National Institutes of Health (NIH), haben eine klinische Studie mit 77 Patienten g...

ResearchPool Subscriptions

Get the most out of your insights

Get in touch